Evidence map›Paper›PMID 27128025›Full record

ReviewBritish journal of pharmacology2016

Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine.

Ambra A Grolla, Cristina Travelli, Armando A Genazzani, Jaswinder K Sethi

Open access · hybridAbstract readReview
In one paragraph

Review in British journal of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 111 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Implication of Immunobiological Function of Melanocytes in Dermatology.Clinical reviews in allergy & immunology · 2025
    Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunction.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Article
  18. Article
  19. Article
  20. NADAntioxidants (Basel, Switzerland) · 2023
    Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ambra A GrollaDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara, Italy.ORCID 0000-0003-0233-0700
Cristina TravelliDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara, Italy.ORCID 0000-0002-9721-9572
Armando A GenazzaniDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara, Italy.ORCID 0000-0003-1923-7430
Jaswinder K SethiDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara, Italy.ORCID 0000-0003-4157-0475
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

Biotechnology and Biological Sciences Research Council JF16994British Heart Foundation PG/10/38/28359
6 · The paper itself

Abstract

In this review, we focus on the secreted form of nicotinamide phosphoribosyltransferase (NAMPT); extracellular NAMPT (eNAMPT), also known as pre-B cell colony-enhancing factor or visfatin. Although intracellular NAMPT is a key enzyme in controlling NAD metabolism, eNAMPT has been reported to function as a cytokine, with many roles in physiology and pathology. Circulating eNAMPT has been associated with several metabolic and inflammatory disorders, including cancer. Because cytokines produced in the tumour micro-environment play an important role in cancer pathogenesis, in part by reprogramming cellular metabolism, future improvements in cancer immunotherapy will require a better understanding of the crosstalk between cytokine action and tumour biology. In this review, the knowledge of eNAMPT in cancer will be discussed, focusing on its immunometabolic function as a metabokine, its secretion, its mechanism of action and possible roles in the cancer micro-environment.

Indexed as

AnimalsHumansNeoplasmsNicotinamide PhosphoribosyltransferaseTumor MicroenvironmentNicotinamide Phosphoribosyltransferase

Identifiers

PMID27128025
PMCPMC4919578
OpenAlexW2343462384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.